MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$2,970K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Cost of share-based payments
Proceeds from issuance of common...
(decrease)/increase in accounts ...
Others
Negative Cash Flow Breakdown
Net loss
Issuance costs-At Market Offerin...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-7,020
-6,050
-7,314
-7,462
Cost of share-based payments
1,709
1,850
1,476
1,457
Increase in other current assets
-52
193
-70
-69
(decrease)/increase in accounts payable
489
-1,579
-165
1,462
Decrease in accrued liabilities
56
-79
50
63
Decrease in employee compensation and benefits
183
-460
1,909
-83
Net cash used in operating activities
-4,531
-6,511
-3,974
-4,494
Net cash provided by (used in) investing activities
-
0
-
-
Proceeds from issuance of common shares-At Market Offering
177
7
248
13,550
Issuance costs-At Market Offering
4
-
82
407
Proceeds from issuance of common shares-Public Offering
1,388
-
0
0
Issuance costs-Public Offering
-
-
0
0
Net cash provided by financing activities
1,561
7
166
13,143
(decrease)/increase in cash and cash equivalents
-2,970
-6,504
-3,808
8,649
Cash and cash equivalents at beginning of period
25,130
31,634
35,442
18,533
Cash and cash equivalents at end of period
22,160
25,130
31,634
35,442
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common shares-Public...
$1,388K
(-91.06%↓ Y/Y)
Proceeds from issuance of
common shares-At...
$177K
(-90.62%↓ Y/Y)
Net cash provided by
financing activities
$1,561K
(-90.12%↓ Y/Y)
Canceled cashflow
$4K
(decrease)/increase in cash and cash
equivalents
-$2,970K
(-135.96%↓ Y/Y)
Canceled cashflow
$1,561K
Cost of share-based
payments
$1,709K
(-44.85%↓ Y/Y)
(decrease)/increase in accounts
payable
$489K
(-80.27%↓ Y/Y)
Decrease in employee
compensation and benefits
$183K
(138.53%↑ Y/Y)
Decrease in accrued
liabilities
$56K
(106.68%↑ Y/Y)
Increase in other current
assets
-$52K
(-137.14%↓ Y/Y)
Issuance costs-At Market
Offering
$4K
(-93.22%↓ Y/Y)
Net cash used in
operating activities
-$4,531K
(39.92%↑ Y/Y)
Canceled cashflow
$2,489K
Net loss
-$7,020K
(39.83%↑ Y/Y)
Buy us a coffee
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)